INCY

Incyte Corporation Press Releases

$75.58
*  
3.96
5.53%
Get INCY Alerts
*Delayed - data as of Dec. 17, 2014  -  Find a broker to begin trading INCY now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    INCY Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis
12/9/2014 7:00:00 AM - PR Newswire


Jakafi® (ruxolitinib) receives expanded approval for treatment of polycythemia vera; available through Diplomat
12/5/2014 4:35:00 PM - PR Newswire


FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera
12/4/2014 10:55:00 AM - Business Wire
▲2.27 % Price Change since this news event. The Volume Ratio is 1.17.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Multiple Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting Showcase Incyte's Leadership in the Field of Myeloproliferative Neoplasms (MPNs)
12/2/2014 1:15:00 AM - Business Wire
▲1.79 % Price Change since this news event. The Volume Ratio is 0.77.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Incyte Reports 2014 Third-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
10/30/2014 7:00:00 AM - Business Wire
▲30.60 % Price Change since this news event. The Volume Ratio is 2.14.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Incyte to Present at the Nomura BioPharma Conference
10/23/2014 8:00:00 AM - Business Wire
▲44.04 % Price Change since this news event. The Volume Ratio is 1.03.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Incyte Appoints David Gryska as Executive Vice President and Chief Financial Officer
10/17/2014 8:00:00 AM - Business Wire
▲46.76 % Price Change since this news event. The Volume Ratio is 1.34.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Incyte to Report Third Quarter 2014 Financial Results on October 30
10/15/2014 8:00:00 AM - Business Wire
▲62.40 % Price Change since this news event. The Volume Ratio is 1.16.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Incyte Earns $60 Million Milestone Related to Reimbursement of Jakavi® (ruxolitinib) in Europe
10/2/2014 7:30:00 AM - Business Wire